Is monitoring of anti-factor Ⅹa levels required for low molecular weight heparin prophylaxis of venous thromboembolism in critically ill patients?
10.3760/cma.j.cn121430-20231103-00937
- VernacularTitle:重症患者低分子肝素预防静脉血栓栓塞症需要监测抗Ⅹa因子水平吗？
- Author:
Mengxi DING
1
;
Yachan NING
;
Lipo SONG
;
Peijuan LI
;
Fangfei XIE
;
Shuangling LI
;
Chunmei WANG
Author Information
1. 首都医科大学宣武医院全科医学科，北京 100053
- Keywords:
Critically ill patient;
Low molecular weight heparin;
Venous thromboembolism;
Anti-factor Ⅹa level
- From:
Chinese Critical Care Medicine
2024;36(5):461-464
- CountryChina
- Language:Chinese
-
Abstract:
The incidence and mortality of venous thromboembolism (VTE) are high in critically ill patients, and there is still a risk of VTE and bleeding after the use of fixed-dose low molecular weight heparin (LMWH) for prophylaxis. The level of anti-factor Ⅹa is not up to standard after LMWH prophylaxis in patients with surgery or trauma. The condition of critically ill patients is complicated, and the proportion of patients with low antithrombin Ⅲ is high, which can affect the prophylactic efficacy of LMWH and contribute to VTE occurrence. There is currently no consensus on whether adjusting LMWH dose according to anti-factor Ⅹa levels can reduce VTE occurrence in critically ill patients. High-quality multicenter randomized controlled studies are needed in the future to establish new approaches for precise prevention of VTE in critically ill patients.
